Psoriasis by the numbers

The majority of progress in drug development for psoriasis has been in biologics for severe disease, even though that patient population accounts for a small percentage of overall psoriasis patients. Incyte Corp. believes its topical JAK inhibitor will address the numerically larger mild to moderate patient population with the potential to provide efficacy comparable to therapies for severe disease.

Last week, Incyte's INCB18424 met the primary endpoint in a Phase IIb trial to treat mild to moderate psoriasis...